Vireo Closes FLUENT Acquisition, Issues 6.15M Shares and Adds 33 Dispensaries
VREOF is trading near its 52-week low of $5.95 (5.7% above the low).
Summary
Vireo completed its all-stock acquisition of FLUENT, issuing 6.15 million shares, including 4.73 million to lenders who converted about $35.7 million of FLUENT debt. Chicago Atlantic's stake rises to roughly 11.7%.
Key Events · M&A and Partnerships · VREOF
-
FLUENT Acquisition Closes
Vireo completed the previously announced acquisition of FLUENT Corp. on November 9, 2026, issuing 6,148,780 Vireo shares in aggregate at an exchange ratio of 0.002351197 per FLUENT share.
-
Lender Debt-for-Equity Conversion
Immediately before closing, FLUENT senior lenders converted about $35.7 million of debt into 2,011,455,727 FLUENT shares, exchanged for 4,729,326 Vireo shares subject to six-month lock-ups.
-
Chicago Atlantic Stake Rises to 11.7%
Chicago Atlantic's group acquired 3,884,062 Vireo shares in the equitization, taking its holdings from 3,586,141 shares (6.2%) to 7,470,203 shares (~11.7%) on an as-converted basis; CEO John Mazarakis is a partner of Chicago Atlantic Group.
-
Footprint Expands in Florida
The deal adds 33 dispensaries and roughly 117,000 square feet of cultivation and production capacity, bringing Vireo to about 74 operational dispensaries and 317,000 square feet of capacity.
Analysis · VREOF · Life Sciences
The FLUENT deal Vireo first announced in April has closed, adding 33 dispensaries and roughly 117,000 square feet of cultivation in Florida plus Buffalo, New York operations. That pushes the platform to about 74 dispensaries and 317,000 square feet of capacity in its key market. Consideration was stock, not cash: 6,148,780 Vireo shares in total, of which 4,729,326 went to FLUENT's senior lenders who converted about $35.7 million of debt into equity just before closing. That conversion is what matters for shareholders. Chicago Atlantic's group went from 6.2% to roughly 11.7% of Vireo on an as-converted basis, and CEO John Mazarakis is a partner of Chicago Atlantic Group, so a related party now holds a materially larger stake. Six-month lock-ups on the lender shares limit near-term selling pressure, but the equity overhang is real. Two FLUENT units are being sold off right after closing: Etain in New York, with Buffalo assigned to Vireo-affiliated Ace Heritage, and Cansortium Texas. Both still await regulatory approval, so the final footprint and proceeds are not yet settled.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VREOF was trading at $6.29 on OTC in the Life Sciences sector, with a market capitalization of approximately $367.8M. The 52-week trading range was $5.95 to $21.76. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.